The litigation, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., alleges that the company misled shareholders regarding the market performance of its core product portfolio. According to the complaint filed in the Southern District of New York, Zoetis failed to disclose that demand for its canine pain treatment Librela was flagging following reports of neurological complications. The suit further claims that key preventative and dermatological products—including Simparica Trio, Apoquel, and Cytopoint—were losing significant market share to lower-priced competitors throughout the class period.
The stock decline occurred on May 7, 2026, when the company released first-quarter financial results revealing weakness in its companion animal business. Law firm Kessler Topaz Meltzer & Check, LLP is currently evaluating potential recovery options for affected shareholders. While the firm is not the lead counsel in this specific filing, they are advising investors on the process of appointing a lead plaintiff, who acts as the primary representative for the class to direct the litigation.
Comments (0)
No comments yet. Be the first!